Hair Loss Incidence in Key Clinical Trials
Darolutamide, used for non-metastatic castration-resistant prostate cancer, shows low rates of hair loss (alopecia) in pivotal trials. In the ARAMIS trial (phase 3, n=1,709), any-grade alopecia occurred in 1.9% of darolutamide patients versus 0.7% on placebo. Grade 3-5 events were rare at 0.1%.[1][2]
In the ARASENS trial (phase 3, n=1,306, darolutamide plus docetaxel), alopecia incidence was 2.7% (any grade) in the combination arm, compared to 1.2% with placebo plus docetaxel. Most cases were grade 1-2.[1][3]
How Common Is It Compared to Other Androgen Receptor Inhibitors?
Darolutamide has lower alopecia rates than enzalutamide (8-10% any grade in PROSPER/ARCHES) or apalutamide (5-7% in SPARTAN/TITAN), likely due to its lower blood-brain barrier penetration and distinct chemical structure.[1][4]
| Drug | Key Trial | Any-Grade Alopecia (%) |
|------|-----------|------------------------|
| Darolutamide | ARAMIS | 1.9 |
| Enzalutamide | PROSPER | 8.5 |
| Apalutamide | SPARTAN | 6.2 |
Why Does Darolutamide Cause Less Hair Loss?
Its polar structure limits central nervous system exposure, reducing off-target effects on hair follicles compared to non-polar AR inhibitors. Alopecia is typically mild and reversible upon discontinuation.[2][5]
Patient Reports and Real-World Data
Post-marketing data from FDA adverse event reporting (through 2023) lists alopecia in ~2% of darolutamide cases, aligning with trials. Patients often describe it as mild thinning rather than severe baldness.[6]
Does It Happen with Combination Therapy?
In ARASENS (with docetaxel/ADT), rates rose slightly to 2.7%, but docetaxel alone causes alopecia in 10-20% of users, suggesting minimal additive risk from darolutamide.[3]
Sources
[1]: Nubeqa (darolutamide) Prescribing Information
[2]: ARAMIS Trial (NEJM, 2019)
[3]: ARASENS Trial (NEJM, 2022)
[4]: Enzalutamide Prescribing Information
[5]: Fizazi K et al., Lancet Oncol (2020) – AR inhibitor review
[6]: FDA FAERS Database Summary